Skip to main content
Article
Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes
Blood (2019)
  • Guillermo Montalban-Bravo, University of Texas MD Anderson Cancer Center
  • Rashmi Kanagal-Shamanna, University of Texas MD Anderson Cancer Center
  • Christopher B. Benton, University of Texas MD Anderson Cancer Center
  • Caleb Class, University of Texas MD Anderson Cancer Center
  • Kelly S. Chien, University of Texas MD Anderson Cancer Center
  • Koji Sasaki, University of Texas MD Anderson Cancer Center
  • Kiran Naqvi, University of Texas MD Anderson Cancer Center
  • Yesid Alvarado, University of Texas MD Anderson Cancer Center
  • Tapan M. Kadia, University of Texas MD Anderson Cancer Center
  • Farhad Ravandi, University of Texas MD Anderson Cancer Center
  • Jorge E. Cortes, University of Texas MD Anderson Cancer Center
  • Naval G. Daver, University of Texas MD Anderson Cancer Center
  • Koichi Takahashi, University of Texas MD Anderson Cancer Center
  • Courtney D. DiNardo, University of Texas MD Anderson Cancer Center
  • Elias Jabbour, University of Texas MD Anderson Cancer Center
  • Gautam M. Borthakur, University of Texas MD Anderson Cancer Center
  • Naveen Pemmaraju, University of Texas MD Anderson Cancer Center
  • Marina Y Konopleva, University of Texas MD Anderson Cancer Center
  • Sherry A. Pierce, University of Texas MD Anderson Cancer Center
  • Carlos E. Bueso-Ramos, University of Texas MD Anderson Cancer Center
  • Michael Andreeff, University of Texas MD Anderson Cancer Center
  • Keyur P. Patel, University of Texas MD Anderson Cancer Center
  • Hagop M. Kantarjian, University of Texas MD Anderson Cancer Center
  • Guillermo Garcia-Manero, University of Texas MD Anderson Cancer Center
Publication Date
November 13, 2019
DOI
10.1182/BLOOD-2019-124978
Citation Information
Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Christopher B. Benton, Caleb Class, et al.. "Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes" Blood Vol. 134 (2019) p. 1711 - 1711
Available at: http://works.bepress.com/caleb-class/10/